Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference
Cytek Biosciences (NASDAQ: CTKB), a cell analysis solutions company, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL. The company's management will engage in a fireside chat on June 11th at 11:40 a.m. PT / 2:40 p.m. ET. Investors and interested parties can access both live and archived webcasts of the presentation through the company's investor relations website at investors.cytekbio.com.
Cytek Biosciences (NASDAQ: CTKB), un'azienda specializzata in soluzioni per l'analisi cellulare, ha annunciato la sua partecipazione alla 46ª Conferenza Annuale Globale sulla Sanità di Goldman Sachs a Miami Beach, FL. Il management dell'azienda parteciperà a una conversazione informale il 11 giugno alle 11:40 PT / 14:40 ET. Investitori e interessati potranno seguire la presentazione in diretta o in differita tramite webcast sul sito web delle relazioni con gli investitori all'indirizzo investors.cytekbio.com.
Cytek Biosciences (NASDAQ: CTKB), una empresa de soluciones para el análisis celular, anunció su participación en la 46ª Conferencia Anual Global de Salud de Goldman Sachs en Miami Beach, FL. La dirección de la empresa participará en una charla informal el 11 de junio a las 11:40 a.m. PT / 2:40 p.m. ET. Los inversores y partes interesadas podrán acceder a las transmisiones en vivo y archivadas de la presentación a través del sitio web de relaciones con inversores en investors.cytekbio.com.
Cytek Biosciences (NASDAQ: CTKB)는 세포 분석 솔루션 회사로서 골드만 삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 마이애미 비치, 플로리다에서 참가한다고 발표했습니다. 회사 경영진은 6월 11일 오전 11:40 PT / 오후 2:40 ET에 파이어사이드 채팅에 참여할 예정입니다. 투자자 및 관심 있는 분들은 회사 투자자 관계 웹사이트 investors.cytekbio.com에서 생중계 및 아카이브된 웹캐스트를 시청할 수 있습니다.
Cytek Biosciences (NASDAQ: CTKB), une entreprise spécialisée dans les solutions d'analyse cellulaire, a annoncé sa participation à la 46e Conférence Annuelle Globale sur la Santé de Goldman Sachs à Miami Beach, FL. La direction de l'entreprise participera à une discussion informelle le 11 juin à 11h40 PT / 14h40 ET. Les investisseurs et parties intéressées pourront accéder aux webcasts en direct et archivés de la présentation via le site des relations investisseurs à investors.cytekbio.com.
Cytek Biosciences (NASDAQ: CTKB), ein Unternehmen für Zellanalyselösungen, gab seine Teilnahme an der 46. jährlichen globalen Gesundheitskonferenz von Goldman Sachs in Miami Beach, FL, bekannt. Das Management des Unternehmens wird am 11. Juni um 11:40 Uhr PT / 14:40 Uhr ET an einem Fireside-Chat teilnehmen. Investoren und Interessierte können sowohl Live- als auch aufgezeichnete Webcasts der Präsentation über die Investor-Relations-Website des Unternehmens unter investors.cytekbio.com abrufen.
- None.
- None.
FREMONT, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL.
Cytek management is scheduled to participate in a fireside chat on Wednesday, June 11th at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™ and Cytek Aurora™ CS systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
FAQ
When is Cytek Biosciences (CTKB) presenting at the Goldman Sachs Healthcare Conference 2025?
How can I watch Cytek Biosciences' (CTKB) presentation at the Goldman Sachs Healthcare Conference?
Where is the Goldman Sachs Healthcare Conference 2025 being held?
What type of presentation will Cytek Biosciences (CTKB) give at the Goldman Sachs conference?
